Drug interactions are now the greatest impediment in dealing with HIV/HCV co-contaminated patients. Regarding security outcomes, tenofovir DF utilized with ledipasvir or velpatasvir can cause a rise in serum creatinine, especially when combined with a pharmacokinetic booster. [139] The use of tenofovir DF should be avoided in these scenarios in the